PBS Changes from 1 June 2025

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1st June 2025.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit pbs.gov.au. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website. 

Diabetes mellitus type 2

Semaglutide (0.68 mg/mL injection, 1 x 3 mL pen device) (Ozempic@) is now listed on the PBS for the treatment of diabetes mellitus type 2. Authority applications for initial treatment can be made either in real-time using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment are Authority required (STREAMLINED).

Mild to moderate ulcerative colitis; mild to moderate ulcerative proctitis

Mesalazine (1 g/100 mL enema, 7 x 100 mL; 1 g suppository, 28) (Pentasa@) and (2 g/60 mL enema, 7 x 60 mL; 4 g/60 mL enema, 7 x 60 mL; 1g/application foam, 14 applications; 1 g suppository, 30) (Salofalk@) has had a change to the number of repeats from 1 to 5 repeats. Prescriptions for the treatment of mild to moderate ulcerative colitis with the enemas or foam are Authority required (STREAMLINED). The suppositories are listed as a restricted benefit for the treatment of mild to moderate ulcerative proctitis.

Severe asthma; bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease

Tiotropium (tiotropium 2.5 microgram/actuation inhalation solution, 2 x 60 actuations) (Spiriva Respimat@) is now listed on the PBS for the treatment of severe asthma and for the treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease.Prescriptions for the treatment of asthma in patients aged 6 to 17 years inclusive are Authority required (STREAMLINED). It is listed as a restricted benefit for the treatment of asthma in patient aged at least J 8 years of age, and for the treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD)

Tiotropium + olodaterol (tiotropium 2.5 microgram/actuation + olodaterol 2.5 microgram/actuation inhalation solution, 2 x 60 actuations) (Spiolto RespimatO•) is now listed on the PBS for the treatment of COPD. Prescriptions for treatment are Authority required (STREAMLINED).

---

1 June 2025 delisted PBS listings 

Anti-inflammatory / immunosuppressive agent

Methylprednisolone (1 g injection, 1 vial) (SoIu-MedroI@) has been delisted.

Familial heterozygous hypercholesterolaemia; non-familial hypercholesterolaemia  

Inclisiran (284 mg/1.5 mL injection, 1.5 mL syringe) (LeqviOO) no longer has a listing for Grandfather arrangements.

Moderate to severe hidradenitis suppurativa

Secukinumab (150 mg/mL injection, 2 x 1 mL pen devices) (Cosentyx@) no longer has a listing for Grandfather arrangements.

---

For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities.

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html.

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.

For more information go to servicesaustralia.gov.au/hpos. To learn more about these updates, please contact Services Australia directly.

At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.

Follow our LinkedIn and Facebook pages for more information.